Empowering medical professionals to assess, diagnose and manage chronic liver diseases, everywhere, for simpler, faster and better patient care and liver health.
employees over seven subsidiaries
distributors over the world
international patents granted
of annual sales invested in R&D
It’s about passionate and humble people that make us see simplicity out of complexity.
Before becoming a company, echosens was an idea. This idea has been growing from its root in Paris, within Prof. Fink’s lab. Initially, my PhD thesis paved the way for the development of transient elastography (TE), which we patented in 1999.
After Laurent Sandrin’s PhD thesis on transient elastography (TE), this technology found its application to quantify liver stiffness (LSM by VCTE™) allowing a better patient care in hepatology…
The very first FibroScan® launched on the market is the FibroScan® 502. It was released during the EASL Congress in Geneva.
In addition to VCTE™, Echosens introduced a new, unique and patented technology calledCAP™ (Controlled Attenuation Parameter) for liver steatosis assessment, a true benefit to measure patient’s liver fat.
With FibroScan® Mini+ 430 and FibroScan® Compact 530, the FibroScan® family evolves to better fit physicians daily practice with mobility, user-friendliness and connectivity, ideal for multi-site configuration.
Fast™ is the optimal point-of-care comprehensive test for the identification of at risk NASH patients.
The complete non-invasive solution for advanced liver disease management, with the new Spleen Stiffness Measurement (SSM by VCTE™).